Lawyers

Marcie A. Goldstein

Lawyers

Filters

BMC Stock Holdings, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $124.2 million SEC-registered offering of 6,555,000 shares of common stock…

Loxo Oncology, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $41.4 million SEC-registered common stock offering of 1,926,250 shares of common stock of Loxo Oncology, Inc…

Theravance Biopharma, Inc. Follow-On Offering

Davis Polk advised the joint book-running managers in connection with a $115.1 million SEC-registered offering of 5,479,750 ordinary shares of Theravance Biopharma, Inc. The ordinary shares…

Red Rock Resorts Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $531 million initial public offering by Red Rock Resorts Inc. of 27,250,000 shares…

SecureWorks Corp. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $112 million initial public offering by SecureWorks Corp. of 8,000,000 shares of…

Summit Materials Secondary Offering

Davis Polk advised the sole underwriter in connection with the approximately $200 million secondary offering of 10,000,000 shares of common stock of Summit Materials, Inc. by certain…

Aeglea BioTherapeutics, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s…

GoDaddy Inc. $574 Million Secondary Offering

Davis Polk advised the representatives of the several underwriters, in connection with a secondary offering of 18,975,000 shares of Class A common stock of GoDaddy Inc. by certain of…

Corvus Pharmaceuticals, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000…
Back to top